Physician profile
Janet Kelske
NPI 1083663413
$5,620.55
in general payments reported to CMS, 2019-2025
28 companies · $1,237 in 2025
The $1,237 reported for 2025 was more than what 96% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $581 · 2022: $1,163 · 2023: $1,452 · 2024: $1,187 · 2025: $1,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,718 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,718.46 |
| Education | $157.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,179.38 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $1,010.36 | 2021-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $522.73 | 2021-2025 | Nucala, Trelegy Ellipta |
| Incyte Corporation | $315.03 | 2021-2025 | Opzelura |
| Genzyme Corporation | $270.81 | 2021-2024 | |
| Amgen INC. | $256.45 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $251.22 | 2021-2025 | Cuvitru, Eohilia, Hyqvia |
| Optinose US, INC. | $217.51 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $157.43 | 2024-2025 | |
| Csl Behring | $143.81 | 2024-2025 | Hizentra |
| Genentech USA, INC. | $143.50 | 2023-2025 | Xolair |
| Kaleo, INC. | $139.82 | 2021-2024 | Auvi-Q |
| Aytu Biopharma, INC. | $126.53 | 2022-2025 | Karbinal |
| Pfizer INC. | $112.06 | 2021-2025 | |
| Pharming Healthcare, INC. | $106.93 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $104.33 | 2025 | |
| Abbvie INC. | $90.66 | 2023-2025 | |
| Leo Pharma INC. | $77.34 | 2023 | Adbry |
| Alk-Abello, INC | $60.50 | 2021-2023 | Grastek, Odactra, Ragwitek |
| Teva Pharmaceuticals USA, INC. | $59.34 | 2022 | |
| Octapharma USA, INC. | $46.59 | 2025 | Panzyga, Cutaquig |
| Hikma Pharmaceuticals USA | $43.49 | 2023 | Ryaltris |
| Grifols USA, LLC | $43.49 | 2023-2025 | Xembify |
| Lilly USA, LLC | $42.33 | 2025 | Ebglyss |
| Blueprint Medicines Corporation | $37.11 | 2023 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $31.97 | 2025 | Neffy |
| Neos Therapeutics, Lp | $16.59 | 2022 | |
| Biocryst US Sales Co., LLC | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Kelske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.